Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Everolimus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    314 result(s) found for: Everolimus. Displaying page 9 of 16.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2007-001108-19 Sponsor Protocol Number: SAKK 36/06 Start Date*: 2008-09-23
    Sponsor Name:SAKK
    Full Title: Master protocol for mantle cell lymphoma. A multicenter phase II trial testing Everolimus ( RAD001) for the treatment of patients with relapsed or thérapy resistant mantle cell lymphoma. Protocol S...
    Medical condition: Traitement des lymphomes du manteau en deuxième ou troisième ligne (1ère ou 2nd rechute)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061275 Mantle cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-000102-36 Sponsor Protocol Number: Everopolm Start Date*: 2008-02-21
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Immunosoppressive protocol based on everolimus and calcineurin inhibitor low doses in lung transplant recipients with moderate-severe kidney disease after standard immnuotherapy.
    Medical condition: kidney disease after pulmonary transplant
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038474 Renal insufficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003689-41 Sponsor Protocol Number: CRAD001YGB11 Start Date*: 2012-11-19
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A Phase IV multicentre, open label study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with everolimus (RAD001) in combination with e...
    Medical condition: oestrogen receptor positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-014436-38 Sponsor Protocol Number: 2009/07 Start Date*: 2009-09-25
    Sponsor Name:UMCG
    Full Title: A prospective, open, randomized, single center study comparing the effects of duo therapy with Everolimus and steroids versus triple treatment of low dose calcineurin inhibitor, low-dose MMF and st...
    Medical condition: Renal transplantation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-000045-12 Sponsor Protocol Number: PEVERENAL Start Date*: 2013-07-06
    Sponsor Name:Centre François Baclesse
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-001086-20 Sponsor Protocol Number: DP-1111-02CT Start Date*: 2021-10-19
    Sponsor Name:ITM Solucin GmbH
    Full Title: A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient- reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu...
    Medical condition: Well-differentiated Aggressive Grade2 and Grade 3, Somatostatin receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (GEP-NET)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003972-23 Sponsor Protocol Number: hcc1 Start Date*: 2009-01-09
    Sponsor Name:LUMC
    Full Title: Hepatocellular carcinoma: vascular abnormalities prior to, during and following systemic anti-cancer treatment
    Medical condition: The primary objective of this study is to determine the efficacy of the combination of everolimus and capecitabine in a group of patients with metastatic or locally advanced HCC. In addition, to in...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019828 Hepatocellular carcinoma non-resectable LLT
    9.1 10019829 Hepatocellular carcinoma recurrent LLT
    9.1 10008452 Chemotherapy multiple agents systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002874-30 Sponsor Protocol Number: 008424QM Start Date*: 2012-12-10
    Sponsor Name:Queen Mary University of London
    Full Title: AN OPEN LABEL RANDOMISED PHASE II STUDY COMPARING AZD2014 VERSUS EVEROLIMUS IN PATIENTS WITH ADVANCED METASTATIC RENAL CANCER AND PROGRESSION ON VEGF TARGETED THERAPY
    Medical condition: Metastatic Clear Cell Renal Cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-013541-28 Sponsor Protocol Number: RB 09.074 Start Date*: 2009-10-27
    Sponsor Name:CHU de Brest
    Full Title: Intérêt de l’utilisation d’un inhibiteur de la mTor (everolimus) pour la minimisation des anticalcineurines dans les transplantations rénales de type « old for old » (receveur > 60 ans recevant un ...
    Medical condition: Candidat de 60 ans et plus à une greffe rénale et bénéficiant d'un greffon de donneur de 60 ans et plus
    Disease: Version SOC Term Classification Code Term Level
    12.0 10038533 Renal transplant LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003195-12 Sponsor Protocol Number: CHUBX2012/29 Start Date*: 2013-10-01
    Sponsor Name:CHU de Bordeaux
    Full Title: A multicenter, two arms, randomized, open label clinical Phase IV study investigating the proportion of CMV seropositive kidney transplant recipients who will develop a CMV infection within the fir...
    Medical condition: CMV infection in CMV-seropositive de novo kidney transplant recipients receiving an immunosuppressive regimen.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001024-38 Sponsor Protocol Number: AIO-MAM-0110 Start Date*: 2011-07-27
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Vinorelbine In Combination with the mTOR Inhibitor Everolimus vs Vinorelbine monotherapy in Advanced breast cancer
    Medical condition: local advanced metastatic breat cancer, second line therapy for patients who did not respond to treatment with anthracyclines or taxanes or are not suitable for such treatment
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002224-32 Sponsor Protocol Number: FFCD1104 Start Date*: 2013-05-23
    Sponsor Name:Fédération Francophone de Cancérologie Digestive
    Full Title:
    Medical condition:
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-005329-22 Sponsor Protocol Number: iOM-12293 Start Date*: 2014-08-19
    Sponsor Name:iOMEDICO AG
    Full Title: An open label, randomized controlled prospective multicenter two arm phase IV trial to determine Patient preference for everolimus in combination with exemestane or capecitabine in combination wit...
    Medical condition: HER2/neu-negative, ER/PR positive inoperable or metastatic adenocarcinoma of the breast
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002176-39 Sponsor Protocol Number: V3002401 Start Date*: 2022-02-07
    Sponsor Name:Veru Inc.
    Full Title: ARTEST - A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Enobosarm Monotherapy Versus Active Control for the Treatment of AR+/ER+/HER2- Metastatic Breast Cancer in Patients with A...
    Medical condition: (AR+)/estrogen receptor positive(ER+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001898-78 Sponsor Protocol Number: CABOTEM Start Date*: 2020-11-12
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of combination between Cabozantinib and Temozolomide in Lung and GEP-NENs progressive after SSAr, everolimus, sunitinib...
    Medical condition: Patient with Lung and GEP-NENs progressive after SSAr, everolimus, sunitinib or PRRT.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028196 Multiple endocrine neoplasias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022941-72 Sponsor Protocol Number: PMR-EC-1503 Start Date*: Information not available in EudraCT
    Sponsor Name:Astellas Pharma Europe Ltd.
    Full Title: A MULTICENTER, TWO ARM, RANDOMIZED, OPEN LABEL CLINICAL STUDY TO COMPARE RENAL FUNCTION IN STABLE HEART TRANSPLANT RECIPIENTS RECEIVING AN ADVAGRAF® BASED IMMUNOSUPPRESSIVE REGIMEN WITH OR WITHOUT ...
    Medical condition: Prophylaxis of heart transplant rejection.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10050432 Prophylaxis against heart transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) SK (Prematurely Ended) CZ (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-002854-22 Sponsor Protocol Number: CRAD001A2309 Start Date*: 2005-08-02
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 24-month, multicenter, randomized, open label non inferiority study of efficay and safety comparing concentration- controlled Certican in two doses (1.5 and 3.0 mg/day starting doses) with reduce...
    Medical condition: Prevention of the rejection in adult patients receiving a de-novo renal transplant in combination with Neoral and corticosteroids
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) SK (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000133-40 Sponsor Protocol Number: 2016-2369 Start Date*: 2016-05-25
    Sponsor Name:Gustave Roussy
    Full Title: European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
    Medical condition: Relapsed or refractory tumors in children
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-006182-88 Sponsor Protocol Number: CRAD001CDE16 Start Date*: 2009-03-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A single arm, multicenter, single-stage phase II trial of RAD001 in Advanced and Metastatic Silent neuro-Endocrine Tumours in Europe
    Medical condition: Patients with histologically confirmed advanced (unresectable or metastatic) non syndromic NET from foregut, midgut and hindgut, with exclusion of pancreatic NET, who have progressed within 12 mont...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052399 Neuroendocrine tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002920-32 Sponsor Protocol Number: CRAD001HDE10 Start Date*: 2006-01-26
    Sponsor Name:Novartis Pharma GmbH
    Full Title: PRESERVATION OF RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS WITH CERTICAN THERAPY: PROTECT Study A twelve-month, multicenter, randomized, open-label study of safety, tolerability and efficacy of ...
    Medical condition: prophylaxis of organ rejections in adult patients after liver transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jul 04 08:31:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA